
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing flucytosine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing flucytosine are listed in capsule form. No finished flucytosine product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Flucytosine is an oral antifungal that compounding pharmacies prepare as oral suspensions, vaginal creams and other forms by prescription.
Flucytosine (5-fluorocytosine) is an antifungal. Fungal cells pull it in through a transporter they have and human cells lack, then convert it to fluorouracil, which is built into fungal RNA and blocks fungal DNA synthesis, so the fungus cannot make proteins or copy itself. The manufactured product is Ancobon capsules, with several generic flucytosine capsules. They are FDA-approved for serious infections caused by susceptible strains of Candida or Cryptococcus, including septicemia, endocarditis, urinary tract infection and meningitis; because resistance develops when it is used alone, the label calls for combining it with amphotericin B for systemic candidiasis and cryptococcosis. A prescriber may order flucytosine compounded when a patient needs an oral liquid, a lower strength for a child, or a vaginal cream, none of which is manufactured. Compounded flucytosine preparations are not FDA-approved and require a prescription.
Flucytosine carries an FDA boxed warning: use with extreme caution in patients with impaired renal function, and closely monitor blood counts, kidney function and liver function throughout treatment. Because the kidneys clear it, reduced kidney function lets the drug build up to toxic levels. Bone marrow suppression can be irreversible and fatal, especially in immunosuppressed patients. It is contraindicated with complete dihydropyrimidine dehydrogenase (DPD) deficiency or prior hypersensitivity. Liver injury, heart rhythm problems, kidney failure, ataxia and hearing loss have been reported. Cytarabine inactivates flucytosine, and drugs that reduce kidney filtration prolong its half-life. Flucytosine was teratogenic in rats and there are no adequate studies in pregnant women; it is used only when the benefit justifies the risk. It is not known whether it passes into breast milk, and the label advises choosing between nursing and the drug. Common side effects are nausea, vomiting, diarrhea and rash. For unusual bruising, fever, yellow skin, confusion or a drop in urination, talk to your prescriber or pharmacist right away.
Flucytosine enters fungal cells via cytosine permease and is deaminated to 5-fluorouracil, whose metabolites are falsely incorporated into fungal RNA and inhibit thymidylate synthetase, disrupting protein and DNA synthesis. Oral bioavailability is about 78 to 89 percent; protein binding is only about 3 to 4 percent; it is not metabolized and more than 90 percent is excreted unchanged by glomerular filtration. Half-life is 2.4 to 4.8 hours with normal renal function and averaged 85 hours in anuric patients, so dose intervals are adjusted to creatinine clearance and the drug is dialyzable. Labeled indications (Ancobon): serious Candida infections (septicemia, endocarditis, urinary tract) and Cryptococcus infections (meningitis, pulmonary), in combination with amphotericin B for systemic disease. Prescribers have ordered compounded intravaginal flucytosine cream for azole-refractory Candida glabrata vaginitis, where a retrospective series reported clinical success in most treated women with uncommon local side effects (Sobel et al., AJOG 2003). Dosing is per prescriber. Monitor serum flucytosine concentrations, CBC with platelets, renal function and hepatic enzymes at frequent intervals; check electrolytes for hypokalemia before therapy. Flucytosine is not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally